By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit, LinkedIn and follow us on


Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 20,000
Symbol: AMGN

Company News
Amgen (AMGN) Falls After Earnings Update Reveals Embarassingly 'Bare' Pipeline 7/26/2017 8:27:29 AM
Amgen (AMGN) Announces Webcast Of 2017 Second Quarter Financial Results 7/21/2017 8:30:35 AM
Amgen (AMGN) Release: FDA Accepts Biologics License Application For Aimovig (erenumab) 7/21/2017 6:53:21 AM
Amgen (AMGN) And Array BioPharma (ARRY) Announce Preclinical License And Collaboration Agreement In Inflammation 7/18/2017 6:48:44 AM
Ligand (LGND) Enters Into Commercial License And Supply Agreement With Amgen (AMGN) For Rights To Use Captisol In The Formulation Of AMG 330 7/17/2017 9:33:00 AM
Safety Issues Force the FDA to Turn Down Amgen (AMGN), UCB SA's Osteoporosis Drug 7/17/2017 5:46:16 AM
Amgen (AMGN) Submits Regulatory Applications In U.S. And Europe To Include Overall Survival Data In Kyprolis (Carfilzomib) Label 7/14/2017 9:05:27 AM
Amgen (AMGN) Release: Second Phase III Study Shows Kyprolis (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma 7/13/2017 6:38:29 AM
Amgen (AMGN) And Allergan (AGN) To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin (Bevacizumab) 7/13/2017 6:17:29 AM
Amgen (AMGN) Release: FDA Grants Full Approval For BLINCYTO (Blinatumomab) To Treat Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children 7/12/2017 6:39:50 AM